Full Press Release Details
Verify to continue
To continue, please confirm that you're a human (and not a spambot).
Checking if the site connection is secure
vimeo.com needs to review the security of your connection before
proceeding.
KURA Neutral Sentiment
Dr. Erba provides an overview of the KOMET clinical trial program
Key Takeaway: The article mentions Dr. Erba providing an overview of the KOMET clinical trial program. However, it lacks specific details about the trial or its implications. The content is primarily focused on confirming user access to the site, without offering substantial information on the clinical trial itself.
Price reaction · baseline $12.3 (2023-12-15 close) · 4 other KURA headline(s) in the window, move may be shared
day 0 close · peak
+0.4%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+116%
120-day peak, hindsight
Typical move
5.7%
average across 9 past catalysts
Cash runway
~25 mo
Low dilution risk
Lead asset
Tipifarnib
Phase 2 · Leukemia, Myelomonocytic, Chronic